London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Off she goes, a blue /green day is coming
Is that for March 2023 or 2024. Either way it's very good news
Massive potential. This will turn very soon
"Evgen's share price target has been increased to 20p from 18p, as a result, the finnCap analysts added."
https://www.proactiveinvestors.co.uk/companies/news/994909/evgen-pharma-sees-forecasts-upgraded-following-major-partnership-deal-with-stalicla-994909.html
Holdings reduction RNS at CPX, the Newlands, could be selling CPX to buy more here. See post below Tues 9.31 Major Shareholders, the Newlands are listed.
Could it possibly be an institution loading in 100k blocks, without triggering a massive price increase?
And they obviously don't care if the price goes lower (which i suspect, in the short term, it will). it they can buy endless 100k's then they'll continue for the weeks and months to come.
But it's also countered by a big seller, still, who take advantage of any rise to sell also.
i'm ignoring buying until it becomes truly worthwhile, ie. traders get bored and i'll be looking at sub 4.5 before taking some again. and even then i suspect it could drop lower.
but depends on your timeframe... as per the 100k buyer.
Some like this share and are accumulating blocks of 100,000 shares anyways if you look at the trades.
I would expect a loss again tomorrow as many small investors will close out trading positions. I understand that, many trade short term and make money doing it. Given where we started the week I have enjoyed the ride and do not mind the selling. Selling creates opportunity in the near future to add a few on the dips.
Wild swings galore. Need a few sessions to settle down and eventually start a climb. Meantime am building a stake and holding tight. This can be a gem.
Massive potential
Imaging trading for a 10% profit and this bags and rerates again :)
Buys rolling in, traders risk getting locked out!
Why do you say that?
Looking good for a green day
A good strong day ahead
These price swings are hilarious, nonsensical. I guess it'll settle down in a few days.
Fair point mcco,
Always inspires a bit of market confidence when a board buys in and puts some skin in the game!
GLA.
Stalicla deal is worth £165 million (Plus royalties in low to mid double digits on sales of SFX-01)
Hi All Worth Reading Stalicas stance on this deal - take a look at thier team also - one thing the caught my eye is the end royalties are over and above the £160m milestones? They are perpares to fund this fully also - its a big deal IMO
GENEVA, Oct. 10, 2022 /PRNewswire/ -- STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder (ASD).
STALICLA's unique approach addresses a major weakness in the drug development process for NDDs and neuropsychiatric disorders: behaviour is a terrible biomarker. Thanks to DEPI, a proprietary platform aggregating molecular data and human genetic information, STALICLA pushes the frontier of precision medicine further into precision NDDs. DEPI has already reached validation through the clinical identification of biologically defined subgroups of patients with ASD, and their respective candidate treatments. SFX-01 will strengthen STALICLA's pipeline to advance precision medicine for a new subgroup of patient with Autism Spectrum Disorder.
SFX-01 is a patented composition of sulforaphane and alpha cyclodextrin, and the only grade of sulforaphane suitable for clinical research and possible approval as medicine. Thanks to DEPI, STALICLA identified SFX-01 as the best treatment candidate for its second subgroup of patients, ASD-Phenotype 2. SFX-01 in-licensing follows the completion, in early 2022, of Phase 1b for STP1, Stalicla's lead candidate tailored to ASD-Phenotype1, a first subgroup of patients identified by DEPI.
No, they said they’ve been advised still not to buy shares owing to the risk of being accused of insider trading. Seems we should still expect more market responsive company updates to follow, based on their comments.
Stephen 11
Now that the Stalicia deal has been completed, the Board members should be able to trade in the market
They will be getting in at a good time
Lol
And when the TR1 drops tomorrow it will catch them out and ha ha ha ha!!!! Jeremy Clarkson smile! :)